Enfusion (ENFN) to Release Quarterly Earnings on Tuesday

Enfusion (NYSE:ENFN) will release its earnings data before the market opens on Tuesday, August 6th. Analysts expect Enfusion to post earnings of $0.06 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Enfusion (NYSE:ENFN) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). Enfusion had a return on equity of 6.60% and a net margin of 1.40%. The firm had revenue of $48.05 million for the quarter, compared to the consensus estimate of $47.67 million. During the same quarter in the prior year, the firm earned $0.04 EPS. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Enfusion Trading Down 2.1 %

Enfusion stock opened at $9.05 on Monday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of 301.67, a PEG ratio of 2.15 and a beta of 0.92. The stock’s 50 day moving average is $8.87 and its 200-day moving average is $8.98. Enfusion has a 12 month low of $7.52 and a 12 month high of $10.45.

Analysts Set New Price Targets

Separately, Morgan Stanley initiated coverage on shares of Enfusion in a research note on Friday, May 10th. They issued an “overweight” rating and a $11.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Enfusion has an average rating of “Hold” and an average target price of $9.33.

Insider Transactions at Enfusion

In other news, insider Bronwen Bastone sold 18,241 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $8.11, for a total transaction of $147,934.51. Following the completion of the sale, the insider now owns 198,913 shares of the company’s stock, valued at approximately $1,613,184.43. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $8.11, for a total transaction of $147,934.51. Following the sale, the insider now directly owns 198,913 shares of the company’s stock, valued at approximately $1,613,184.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Deirdre Somers sold 4,629 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $8.40, for a total value of $38,883.60. Following the completion of the transaction, the director now owns 43,312 shares of the company’s stock, valued at $363,820.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,318 shares of company stock valued at $296,688. 36.44% of the stock is owned by corporate insiders.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.